Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYNCHRONIZE-CVOT: BI 456906 vs placebo in overweight or obesity with high cardiovascular risk
jRCT2031230478Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2023
- Modality
- Peptides
01
Overview
Phase 3, randomised, double-blind trial in obesity, Overweight, cardiac morbidity and 1 more comparing BI 456906 with Placebo (2 arms). Primary endpoint: Time to first occurrence of composite cardiovascular endpoint. Started Dec 2023; status: completed.
02
Drugs
03
Conditions
obesityOverweightcardiac morbiditychronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCT2031230478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230478.